1	Circulation of Fluconazole-Resistant C. albicans, C. auris and C.
2	parapsilosis Bloodstream Isolates Carrying Y132F, K143R or
3	T220L Erg11p Substitutions in Colombia.
4	Andres Ceballos-Garzon <sup>a, b*</sup> , Ana Peñuela <sup>a, c*</sup> , Sandra Valderrama-Beltrán <sup>d</sup> , Yerly Vargas-
5	Casanova <sup>a</sup> , Beatriz Ariza <sup>c</sup> , Claudia M. Parra-Giraldo <sup>§ a, e.</sup>
6 7 8	<sup>a</sup> Unidad de Proteomica y Micosis Humanas, Grupo de Investigación en Enfermedades Infecciosas, Departamento de Microbiología, Pontificia Universidad Javeriana, Bogotá, Colombia. c-ceballos@javeriana.edu.co (A.C-G.);
9	<sup>b</sup> Université Clermont Auvergne, INRAE, MEDiS, 63000 Clermont-Ferrand, France.
10 11	<sup>c</sup> Laboratorio clínico, Área de Microbiología, Hospital Universitario San Ignacio, Bogotá D.C, Colombia.
12 13	<sup>d</sup> Unidad de Infectología, Departamento de Medicina Interna, Facultad de Medicina, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá D.C, Colombia.
14 15	<sup>e</sup> Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
16 17 18 19	<sup>§</sup> Corresponding author at: Unidad de Proteomica y Micosis Humanas, Grupo de Investigación de Enfermedades Infecciosas, Departamento de Microbiologia, Pontificia Universidad Javeriana, Bogotá, Colombia Carrera 7 # 43-82 Lab 404 Edificio 52, Bogotá, Colombia. E- mail address: claudia.parra@javeriana.edu.co (CP-G).
20	*These authors contributed equally to this work
21	
22	
23	
24	
25 26	
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 27 Abstract

28 Although Candida spp., is a common cause of bloodstream infections and is often associated 29 with high mortality rates, its resistance to antifungal drugs, and the molecular mechanisms 30 involved have been poorly studied in Colombia. Here, 123 bloodstream isolates of Candida 31 spp. were collected. MALDI-TOF MS identification and fluconazole (FLC) susceptibility 32 patterns were assessed on all isolates. Subsequently, sequencing of ERG11, TAC1 or MRR1, 33 and efflux pumps were performed for resistant isolates. Out of 123 clinical strains, C. albicans 34 accounted for 37.4%, followed by C. tropicalis 26.8%, C. parapsilosis 19.5%, C. auris 8.1%, 35 C. glabrata 4.1%, C. krusei 2.4% and C. lusitaniae 1.6%. Resistance to FLC reached 18%. 36 Erg11 amino acid substitutions associated with FLC-resistance (Y132F, K143R or T220L) 37 were found in 58% of 19 FLC-resistant isolates. Furthermore, novel mutations were found in 38 all genes studied. Regarding efflux pumps, 42% of 19 FLC-resistant Candida spp strains 39 showed significant efflux activity. Finally, six of the 19 FLC-resistant isolates neither 40 harbored resistance-associated mutations nor showed efflux pump activity. Although C. 41 albicans remain the most predominant species, non-C. albicans species comprise a high 42 proportion (62.6%). Among FLC-resistant species, C. auris (70%) and C. parapsilosis (25%) 43 displayed the highest percentages of resistance. In 68% of FLC-resistant isolates, a 44 mechanism that could explain their phenotype was found (e.g. mutations, flux pump activity 45 or both). We provide evidence that endemic isolates harbor amino acid substitutions related 46 with resistance to one of the most used molecules in the hospital setting, with Y132F being 47 the most frequently detected one.

48 Key words:

49 *Candida* species, bloodstream infections, fluconazole resistance, *ERG*11, Y132F,
50 Colombia.

#### 51 Introduction

52 Invasive fungal infections (IFIs) due to Candida species are a frequent and life-threatening 53 condition in hospital settings worldwide, and are often associated with high morbidity and 54 mortality [1]. Candida albicans is the most isolated species, with close to a 30% mortality rate 55 in candidemia [2]. However, non-albicans Candida species (NACS) such as C. glabrata and 56 C. parapsilosis have emerged as a common cause, becoming the second or third most 57 frequent species depending on geography, patient underlying condition, and age. For these 58 species, the associated mortality rate is about 50% and 28%, respectively [3,4]. Another 59 important NACS causing candidemia is C. auris, whose mortality rate ranges from 40% to 60 60% according to some studies, despite the fact its prevalence is unclear [5]. 61 While current therapeutic options for IFIs are limited to only three classes of drugs (i.e., 62 polyenes, azoles and echinocandins), the emergence of resistant strains to some of these 63 molecules is even more concerning. For decades, azoles have been the most frequently used 64 antifungal for treating *Candida* infections [6,7]. Although treatment with azoles can be 65 effective, long-term use of fluconazole (FLC) has led to the emergence of *Candida* strains 66 with decreased susceptibility. In the case of Candida spp, the molecular mechanisms behind 67 FLC-resistance have been relatively well characterized [8,9]. 68 Unlike C. auris which is often resistant to FLC, C. albicans and C. parapsilosis isolates were

thought to be universally susceptible to FLC, but recent studies show an increased resistance.
For example, a multicenter laboratory-based survey of candidemia conducted in South Africa
indicates that more than half of *C. parapsilosis* isolates 62% (332/531) are resistant to FLC
[10]. In addition, studies in Brazil, India, Kuwait, South Korea, Spain, Turkey, and the
United States, as well as a recent global study, confirmed the emergence of FLC-resistance in *C. parapsilosis* [11–15]. Regarding *C. albicans*, this species exhibits lower levels of azole

resistance. However, resistant isolates have been reported from many countries around theworld, including Colombia [16–18].

77 The main FLC-resistance mechanisms are associated with *i*) up-regulation of drug

transporters, *ii*) alteration or up-regulation of the gene encoding the enzyme being targeted,

79 which decreases binding affinity for the drug and increases concentration of the enzyme

80 target, *iii*) alterations in the ergosterol synthetic pathway and *iv*) activation of pathways

81 involved in the stress response, such as the Ras/cAMP/PKA pathway, calmodulin/calcineurin

82 pathway (CaM/CaL), and mitogen-activated protein kinase (MAPK) signaling pathways

83 [19,20]. However, the most studied ones are described below.

84 The ATP-binding cassette (ABC) and the major facilitator superfamily (MFS) transporters are

85 responsible for lowering the accumulation of azoles inside the yeast cell by translocating

86 compounds actively across the cell membrane [21]. Overexpression of genes encoding drug

87 transporters, e.g., Cdr1/2-ABC and Mdr1/Flu1-MFS, among resistant isolates of *Candida* 

88 species is predominantly due to gain-of-function (GOF) mutations in genes encoding zinc

89 cluster transcription factors, such as TAC1 (transcriptional <u>a</u>ctivator of <u>CDR</u> genes) and MRR1

90 (<u>multidrug r</u>esistance <u>r</u>egulator). For instance, GOFs in *TAC*1 (T225A, R693K, A736V,

91 H741, N972D, G980E, N997D) and *MRR*1 (I283R, R479K, G583R, V854A, K873N), lead to

92 overexpression of *CDR*1 and *MDR*1 in *C. albicans and C. parapsilosis*, respectively [22,23].

93 Overexpression of *ERG*11, the gene encoding lanosterol  $14\alpha$ -demethylase, the azole target,

94 contributes directly to resistance as the increased abundance of the target requires higher drug

95 doses for inhibition. Activating mutations in the gene encoding the transcription factor Upc2,

96 which up-regulates most ergosterol biosynthesis genes, and the formation of an

97 isochromosome with two copies of the left arm of chromosome 5 [i(5L)], or by duplication of

98 the whole chromosome, on which *ERG*11 resides, are responsible for *ERG*11 overexpression

99 [24]. Furthermore, point mutations in the *ERG*11 alter the 3D conformation of Erg11 and

reduce its affinity for FLC. Some of the most frequent amino acid substitutions reported are
Y132F and K143R substitutions, described in *C. albicans, C. parapsilosis* and *C. auris*[15,25,26].

Although *Candida* isolates from individual institutions may not be representative of the data of a country, such studies can provide a useful baseline snapshot of species distribution and antifungal susceptibility for candidemia in resource-limited settings [10]. In Colombia, there is a lack of data available about antifungal resistance and its molecular mechanisms in *Candida* spp. Therefore, this study aimed to investigate the prevalence of resistance and to describe the mechanisms behind FLC-resistance in a collection of bloodstream isolates.

#### 109 Materials and methods

#### 110 Study design

111 The study was a single-center retrospective analysis. One hundred twenty-three bloodstream

112 isolates of *Candida* spp. obtained from hospitalized patients (2016-2020) of the San Ignacio

113 Hospital in Bogota, Colombia were included. Prior to storage at -80 °C, yeast from blood

114 cultures submitted for routine work-up to the Clinical Microbiology Laboratory were

115 primarily identified using MicroScan (MicroScan WalkAway-96 Plus, Siemens, Deerfield, IL,

116 USA) or VITEK 2 system (bioMérieux, Marcy-l'Etoile, France), and further characterized

117 (this study) using the MALDI-TOF Biotyper system (Bruker Daltonik, Bremen, Germany).

#### 118 **2.2 MALDI-TOF MS**

119 Isolates were streaked from a glycerol stock onto Sabouraud dextrose agar (SDA) and grown

120 for 24–36 h at 35 °C. Protein extraction was performed using formic acid/ethanol method,

121 according to the Bruker Daltonics' protocol. The protein mass spectra were analysed using the

122 Flex Control software and the MALDI Biotyper version 3.1 7311 reference spectra (main

123 spectra) (Bruker Daltonics, Bremen, Germany). MALDI-TOF MS results were obtained

- 124 according to the manufacturer's technical specifications, as follows: correct genus and species
- identification ( $\geq$ 2.0), correct genus identification (1.7–2.0), and no reliable identification
- 126 (< 1.7). All clinical isolates had a score above 2.0 [27].

#### 127 **2.3 Antifungal susceptibility testing**

128 Susceptibility to FLC (Sigma-Aldrich, St. Louis, MO, USA) was conducted using the Clinical

and Laboratory Standards Institute broth microdilution method (CLSI-BMD), following the

130 M27-A3 document [28]. Briefly, isolates were suspended in 1 mL phosphate buffered saline

131 (PBS) and diluted in liquid RPMI 1640 medium to  $10^3$  cells/mL in a 96-well plate, containing

132 a gradient of two-fold dilutions per step of antifungal, with the first well containing no drug.

133 Minimum inhibitory concentrations (MICs) were visually, and densitometry determined as the

134 lowest concentration of drug that caused a significant diminution (MIC/2 or >50%) compared

135 with that of the drug-free growth control after 24 h of incubation. Quality control was ensured

136 by testing the CLSI-recommended strains *C. parapsilosis* ATCC 22019 and *C. krusei* ATCC

137 6258. For NACS isolates the CLSI breakpoints were applied (resistance to FLC was set at *C*.

138 *albicans, C. tropicalis, and C. parapsilosis*  $\geq 8\mu g/mL$  and *C. glabrata*  $\geq 64\mu g/mL$ ) [29]. In the

139 case of *C. auris*, the FLC breakpoint recommended by the US Centers for Disease Control

140 and Prevention (CDC) was used ( $\geq$ 32 µg/mL) [30]. The MIC data obtained under routine

141 conditions for amphotericin B (AMB), caspofungin (CAS), itraconazole (ITC), and

142 voriconazole (VRC) by Etest® (bioMérieux, Marcy-l'Étoile, France) and VITEK®2

143 (bioMérieux) are presented in **Table S1**.

### 144 Sequencing analysis of Erg11, Tac1 and Mrr1-encoding genes

145 All isolates displaying resistance to FLC, and one susceptible isolate of each species were

- subjected to a single-tube PCR method to amplify and sequence the coding region of
- 147 the *ERG11*, *TAC*1 or *MRR*1 genes (both strands) using the primers indicated in **Table S2**. The

148 PCR products were purified and sequenced using a SeqStudio genetic analyzer capillary 149 sequencer (Applied Biosystems). The sequencing results were analyzed by BLAST and 150 compared with the published GenBank sequences: C. albicans AY856352.1 (ERG11), 151 DQ393587 (TAC1), and C. parapsilosis GQ302972 (ERG11), HE605205 (MRR1). For C. 152 *auris*, sequences download from the Candida genome database (candidagenome.org) were 153 used, i.e., B9J08 001448 (C. auris B8441, ERG11) and B9J08 004820 (TAC1b). All 154 sequences (FLC-susceptible and resistant clinical isolates plus reference strains) were aligned, 155 and the dataset was used to construct a Neighbor-Joining phylogenetic tree using Maximum 156 Composite Likelihood settings by using Molecular Evolutionary Genetics Analysis Version 157 11 (MEGA11) [31,32]. Codon positions included were 1st + 2nd + 3rd + Noncoding. All 158 positions containing gaps and missing data were eliminated. Evaluation of branch support was

159 performed by Bootstrap statistical analysis with 1000 replicates [31].

#### 160 Analysis of rhodamine 6G efflux

161 ABC transporter-mediated efflux was determined using rhodamine 6G (Sigma-Aldrich,

162 USA) as previously described [33]. The fluorescence of the released R6G was measured at

163 530 nm, with an emission at 560 nm in an automated plate reader (Model 550 Microplate

164 Reader Bio-Rad, Milan, Italy). Measurements were made before (basal) and after the addition

165 of 20 mM glucose. Using a R6G calibration curve, the fluorescence intensity was converted

166 into concentration.

#### 167 **Statistics**

Experiments were performed in triplicate, in three independent experimental sets. The results were analyzed statistically by the Analysis of Variance One-Way ANOVA. All the analyses were performed using GraphPad Prism version 9 software. In all analyses, p values of 0.05 or less were considered statistically significant.

#### 172 **Results**

#### 173 Identification and Antifungal susceptibility testing of clinical isolates

- 174 The *Candida* species distribution from the 123 blood samples was as follows: *C. albicans*, 46
- 175 (37.4%); *C. tropicalis*, 33 (26.8%); *C. parapsilosis*, 24 (19.5%); *C. auris*, 10 (8.1%); *C.*
- 176 glabrata, 5 (4.1%); C. krusei, 3 (2.4%); and C. lusitaniae, 2 (1.6%). Although C. albicans
- 177 was the most prevalent species, accounting for 37.4%, the NACS group comprised 62.6% of
- the isolates identified. Concerning susceptibility, when applying the CLSI and CDC
- breakpoints, 22 out of 123 (18%) isolates displayed *in vitro* resistance to FLC, among them,
- 180 six of *C. albicans*, six of *C. parapsilosis* and seven of *C. auris* (19/23). Moreover, three
- 181 isolates of *C. krusei* -as *C. krusei* is assumed to be intrinsically resistant to FLC-, were not
- 182 included within the molecular study. In contrast, all isolates of *C. tropicalis*, *C. glabrata*, and
- 183 *C. lusitaniae* were FLC-susceptible **Figure 1**.
- 184 The MICs values obtained for FLC are shown in **Table 1**. The MIC<sub>90</sub> values (MICs at which
- 185  $\geq$  90% of strains are inhibited) for the four most frequent species found were: *C. albicans*
- 186 128µg/mL, *C. tropicalis* 2µg/mL, *C. parapsilosis* 32µg/mL and *C. auris* >128µg/mL. As
- 187 expected, *C. auris* presented the highest MIC<sub>90</sub> values. In addition, the range of FLC MICs
- 188 was narrower for *C. auris* and *C. glabrata* than for the other species. On the other hand, *C.*
- 189 *tropicalis* showed reduced susceptibility to FLC (MIC<sub>90</sub>=  $2\mu g/mL$ ). Regarding VRC MICs
- 190 (data obtained by Etest), 10 out of 19 FLC-resistant isolates, excluding *C. krusei*, were VRC
- 191 cross-resistant. The highest MICs were observed for *C albicans* ( $32 \mu g/mL$ ) **Table S3.**

# 192 Detection of mutations in Erg11, Tac1 and Mrr1-encoding genes of 19 FLC-resistant 193 isolates.

- 194 By comparing the *ERG*11 coding region of *C. albicans* (CAAL, A-F), *C. auris* (CAAU, A-G)
- 195 and C. parapsilosis (CAPA, A-F) FLC-resistant isolates with that of our FLC-susceptible and

196 the published wild-type sequences, we identified 20, 16, and three mutations, respectively. As 197 expected, some silent mutations that do not change the protein sequence were identified (data 198 not shown). The remaining ERG11 mutations which resulted in amino acid changes are 199 shown in Figure 2, Table S4. Among the nonsense mutations (C. albicans 6; C. auris 5; and 200 C. parapsilosis 2), three amino acid substitutions related with FLC-resistance (T220L, 201 Y132F, K143R) were found from which Y132F was the most detected. Additionally, five 202 amino acid substitutions previously described in FLC-susceptible isolates were observed 203 (D116E, K128T, K177R, N335S, E343D). To the best of our knowledge, four amino acid 204 substitutions (K22E, Q38T, F72V, Q77S) have not been previously reported. Overall, eight of 205 the 19 FLC-resistant isolates did not have resistance-associated substitutions. 206 On the other hand, except for isolate CAAL-A, which harbored a K128T substitution in only 207 one ERG11 allele, other isolates were homozygous for mutations in the ERG11 allele. In the 208 phylogenetic relationship among FLC-resistant, susceptible isolates and reference strains, a 209 cluster of isolates carrying the substitutions Y132F in C. auris was observed, as well as in the 210 FLC-resistant C. albicans isolates harboring K128T substitution. In addition, susceptible and 211 resistant isolates without resistance-associated ERG11 mutations (i.e., T220L, Y132F) from 212 these species were clustered Figure 2A-B. 213

Concerning *TAC1* (*C. albicans* and *C. auris*) and *MRR1* (*C. parapsilosis*) genes, no mutations previously associated with FLC-resistance were found. However, 17 Tac1 (*C. albicans*, n=7; *C. auris*, n=10) and Mrr1 (*C. parapsilosis*, n=1) amino acid substitutions previously described in FLC-susceptible isolates were found. Additionally, there were 37 unreported substitutions in Tac1 (*C. albicans*, n=7; *C. auris*, n=26) and Mrr1 (*C. parapsilosis*, n=4) **Figure 2, Table S3.** 

#### 219 Efflux Pumps activity

220 To gain further insights into the mechanisms of azole resistance in the clinical isolates the 221 activity of efflux pumps was evaluated using rhodamine 6G, which uses the same membrane 222 ABC transporters (Cdr1p and Cdr2p) as FLC in *Candida*. Among the 19 FLC-resistant 223 isolates, eight of them showed significant active efflux of rhodamine-6G after addition of 224 glucose: two of them belonging to C. albicans (CAAL-C and CAAL-E); four to C. auris 225 (CAAU-A, CAAU-B, CAAU-C and CAAU-G) and two to C. parapsilosis (CAPA-C, CAPA-F) Figure 3, Figure 1S. Interestingly, no amino acid substitutions associated with FLC-226 227 resistance were identified in both C. albicans isolates (CAAL-C, 128µg/mL), (CAAL-D, 228 128µg/mL). Regarding the remaining isolates that showed efflux pump activity, C. auris 229 (CAAU-A, CAAU-B, CAAU-C, CAAU-G) and C. parapsilosis (CAPA-C, CAPA-F) 230 harbored the Y132F substitution.

In summary, 11/19 resistant isolates harbored an amino acid substitution associated with

FLC-resistance; 8/19 displayed efflux pumps activity; 6/19 had both amino acid substitutions

and efflux pump activity; and 3/19 isolates did not exhibit any of the mechanisms that could

explain their resistant phenotype **Figure 4**.

#### 235 **Discussion**

236 Our study agrees that the three species most found in bloodstream infections in Latin America

are *C. albicans*, *C. tropicalis* and *C. parapsilosis* [34,35]. However, the percentage of *C.* 

tropicalis (26.8% vs. 13.6%) and *C. parapsilosis* (19.5% vs. 13.6%) found differs from that

observed in the first decade of the 2000s in Colombia [36]. Similar results were found for

- species distribution in studies conducted at the same hospital between 2003 and 2014,
- however, we observed a slight increase in NACS (62,6% vs. 58%) and the presence of *C*.
- 242 *auris*, which was not described in these studies [37,38]. In the region, a study that evaluated
- susceptibility of the species identified in Colombia, Ecuador, and Venezuela, found a
- 244 percentage of resistance to FLC of 6.8% [39]. This shows that there is an important change in

the distribution and rate of resistance, which in our study reached 18%. Nevertheless, the

- 246 majority of *C. albicans* isolates were azole susceptible, thus the observed resistance
- 247 percentage is mainly attributed to the presence of *C. auris*, which agrees with previous studies
- [35,40]. Furthermore, it is noteworthy that 25% of the *C. parapsilosis* isolates were resistant
- to FLC, which confirms the increase of resistance in this species Figure 5 [41]. High azole
- 250 resistance rates have been reported for this species in other single-center studies conducted in
- 251 Brazil (67.9%), Italy (33%), France (9.2%), Mexico (54%), Saudi Arabia (33%), Spain
- 252 (13.6%), South Africa (78%) or Turkey (26.4%) [11,13,42–46].
- 253 Overall, the global data indicate that *C. albicans* remains the predominant species identified in
- 254 Candida infections. Herein, C. albicans was the most predominant species, nevertheless,
- 255 NACS accounted for a high proportion (62.6%). Although reported resistance rates vary from
- study to study, the surveillance data collected suggest that azole resistance rates for *C*.
- albicans remain low [35,47]. Remarkably, in this study, the percentage of FLC resistance in
- 258 *C. albicans* was 15%, which is relatively high.
- However, *C. albicans* infections in the bloodstream pose a considerable threat in
- 260 immunocompromised populations and the associated high mortality remains a major problem
- in the clinical setting. Therefore, *C. albicans* should not be overlooked as a serious public
- health threat.
- 263 The acquisition of azole resistance is a serious concern given the limited number of molecules
- available for the treatment of IFIs. Moreover, this is much more worrying in resource-limited
- regions where FLC is the only available therapy [48]. As previously described, azole
- resistance is mainly conferred by mutations in the *ERG*11 gene and by the activity of efflux
- 267 pumps. The *ERG*11 gene is highly polymorphic and more than 140 amino acid substitutions
- have been reported, indicating that this protein is very permissive to conformational changes.

269 Most substitutions occur in three amino acid hotspot regions (105-165, 266-287 and 405-488), 270 although mutations outside these regions can also be found [49,50]. 271 In the present study, 11 of the 19 FLC-resistant isolates harbored mutations which have been 272 previously described in resistant isolates (T220L, Y132F, K143R) [11,51]. Notably, the 273 T220L substitution was observed in one C. albicans isolate. In C. auris, five isolates carried 274 the Y132F, and in the case of C. parapsilosis four isolates harbored the Y132F and one the 275 K143R substitution. 276 The substitution of lysine for threonine at position 128 (K128T) was found in CAAL-A, 277 CAAL-B and CAAL-D isolates, which is consistent with the findings of Cernicka et al., and 278 Peron *et al.*, who identified this amino acid substitution in FLC-resistant strains [52,53]. 279 However, several studies refute this association because K128T substitution has been found in 280 multiple FLC-susceptible isolates, hence, in this study, we do not consider it as a mutation 281 associated with resistance [25,54]. Nevertheless, it might influence translation efficiency, 282 leading to alterations in protein production as it occurs with nearby mutations such as G129R 283 and Y132F [55]. 284 According to Chow and coworkers, mutations contributing to FLC resistance are clade-285 specific in C. auris, being Y132F and K143R the most predominant in clade I, F126L in clade 286 III, and Y132F in clade IV. However, Y132F in Erg11 is the most prevalent one [26]. As 287 described for isolates of clade IV (South America), we found only one mutation: Y132F. 288 Concerning C. parapsilosis, high prevalence of the Y132F substitution was also noted in 289

- 290 mutation may have a higher propensity to cause clonal transmission and to persist in

previous studies [56,57]. In addition, the latter suggested that isolates harbouring this

- 291 nosocomial settings [58]. Regarding our isolates, the Y132F substitution was detected in four
- 292 out of six C. parapsilosis isolates. However, considering the dates of collection of the isolates,
- 293 It does not seem to be a clonal spread (Table S3).

294 Although previous studies indicate that the Mrr1 substitutions I283R, R479K, G583R, 295 A854V, K873N and L986P are associated with FLC and/or VRC resistance, none of our 296 isolates harbored them [59]. Similar to Tac1, residues located near the C terminus (760, 761, 297 803, 956, and 966) might contribute to azole resistance [47]. 298 This study also illustrates that acquired azole resistance commonly relies on combined 299 molecular mechanisms in clinical isolates. In addition to amino acid substitutions in Erg11, 300 six of the 19 isolates also displayed active efflux activity. Interestingly, in two isolates lacking 301 resistance-related mutations, efflux pumps activity was observed. Considering that efflux 302 pumps play a key role in azole resistance, this might be the explanation for the observed 303 phenotype. However, a further study evaluating the expression of all genes involved in efflux 304 pump activity is required.

305 Regarding the isolates in which no mechanism for resistance was found, namely CAAL-A-E,

306 CAAU-D, CAAU-E and CAPA-A, six novel Tac1 or Mrr1 substitutions (G52R, V366del,

307 F682T, F683L, T695S and P229A) were identified in three of the five isolates. Moreover,

308 four novel Erg11 substitutions (K22E, Q38T, F72V, Q77S) in the FLC resistant *C. albicans* 

309 (CAAL-B, CAAL-C) and *C. auris* (CAAU-B) were found. The putative role of these

310 substitutions remains to be investigated. In isolates CAAL-A-D and CAAU-E, a different

311 mechanism to those evaluated here should confer resistance; further analysis is ongoing.

312 Our study has some limitations. For instance, the AST data obtained for antifungals other than

313 FLC are not complete and were not performed by BMD. The molecular basis of FLC

resistance was investigated only by analysis of the *ERG*11, *TAC*1, and *MRR*1 genes, while

315 other mechanisms conferring resistance, such as sterol composition and gene expression, were

316 not investigated due to lack of funds. Finally, the clinical description of the patients was

317 missing and will be reported alongside other patients infected by *Candida* antifungal resistant

318 strains elsewhere.

319	Recently, the WHO published a list of priority pathogenic fungi (FPP) which includes C.
320	albicans, C auris (Critical group), and C. parapsilosis (high group). The WHO describes that
321	to overcome the lack of knowledge on infections caused by these fungi, more data and
322	evidence on fungal infections and antifungal resistance to inform and improve response to
323	FPP is needed [60]. Although our study does not have a large number of isolates and does not
324	include other healthcare institutions, we provide evidence of endemic isolates harboring
325	resistance mutations to one of the most used molecules in the hospital setting.
326	In conclusion, we describe the presence of <i>Candida</i> spp isolates harboring Erg11 FLC
327	resistant-related substitutions (Y132F, K143R and T220L) in patients admitted to a
328	Colombian hospital. Although FLC-resistance rates differ significantly between countries and
329	individual health facilities, the resistance rate in our study is relatively high, emphasizing the
330	need for active surveillance to prevent further expansion of FLC-resistant Candida spp
331	isolates in the clinical setting.

#### 332 Funding

333 The research office of Hospital Universitario San Ignacio and the Vice-Rectory of research at

the Pontificia Universidad Javeriana in Bogotá, Colombia, supported the research (grants

335 no.2014-52 and 20454).

#### 336 Ethics approval and consent to participate

337 The research and ethics committee of the Hospital Universitario San Ignacio (HUSI)

approved this study (no. FM-CIE-8053-14). All patients are anonymized and only the code of

- isolates was transferred for this investigation. Therefore, no informed consent was required.
- **340 Competing interests**
- 341 The authors declare that they have no competing interests.
- 342 Author contributions:

343	AP ca	arried out the experiments; Y.V-C contributed to the development of efflux pumps
344	proto	col; AC-G, and AP analyzed the data; AC-G wrote the main manuscript; AP, SV-B, BA,
345	and C	CP-G review and editing; and CP-G conceived the experiments and managed the
346	resou	rces. All authors have read and agreed to the published version of the manuscript.
347	Refer	rences
348	1	Koehler P, Stecher M, Cornely OA et al. Morbidity and mortality of candidaemia in
349		Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 2019; 25: 1200–1212.
350	2	Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive
351		candidiasis. Nat Rev Dis Prim 2018; 4: 1–20.
352	3	Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of
353		Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur
354		J Clin Microbiol Infect Dis 2005; 24: 23–30.
355	4	Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological
356		landscape of invasive candidiasis. J Antimicrob Chemother 2018; 73: i4-i13.
357	5	Chen J, Tian S, Han X et al. Is the superbug fungus really so scary? A systematic
358		review and meta-analysis of global epidemiology and mortality of Candida auris. BMC
359		Infect Dis 2020; 20: 827.
360	6	Carradori S, Ammazzalorso A, De Filippis B et al. Azole-Based Compounds That Are
361		Active against Candida Biofilm: In Vitro, In Vivo and In Silico Studies. Antibiot 2022,
362		<i>Vol 11, Page 1375</i> 2022; <b>11</b> : 1375.
363	7	Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents.
364		<i>Clin Microbiol Rev</i> 1999; <b>12</b> : 40–79.
365	8	Morio F, Jensen RH, Le Pape P, Arendrup MC. Molecular basis of antifungal drug

366		resistance in yeasts. Int J Antimicrob Agents 2017; 50: 599–606.
367	9	Carolus H, Pierson S, Muñoz JF et al. Genome-wide analysis of experimentally
368		evolved candida auris reveals multiple novel mechanisms of multidrug resistance.
369		<i>MBio</i> 2021; <b>12</b> . doi:10.1128/mBio.03333-20.
370	10	Govender NP, group on behalf of the T-SA, Patel J et al. Emergence of azole-resistant
371		Candida parapsilosis causing bloodstream infection: results from laboratory-based
372		sentinel surveillance in South Africa. J Antimicrob Chemother 2016; 71: 1994–2004.
373	11	Arastehfar A, Daneshnia F, Hilmioglu-Polat S et al. First report of candidemia clonal
374		outbreak caused by emerging fluconazole-resistant candida parapsilosis isolates
375		harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother
376		2020; 64. doi:10.1128/AAC.01001-20/SUPPL_FILE/AAC.01001-20-S0001.PDF.
377	12	Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA. Analysis of
378		global antifungal surveillance results reveals predominance of Erg11 Y132F alteration
379		among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific
380		isolate dissemination. Int J Antimicrob Agents 2020; 55.
381		
501		doi:10.1016/J.IJANTIMICAG.2019.09.003.
382	13	doi:10.1016/J.IJANTIMICAG.2019.09.003. Díaz-García J, Gómez A, Alcalá L <i>et al.</i> Evidence of Fluconazole-Resistant Candida
	13	
382	13	Díaz-García J, Gómez A, Alcalá L et al. Evidence of Fluconazole-Resistant Candida
382 383	13	Díaz-García J, Gómez A, Alcalá L <i>et al.</i> Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and
382 383 384	13	Díaz-García J, Gómez A, Alcalá L <i>et al.</i> Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution. <i>Antimicrob Agents Chemother</i> 2022; <b>66</b> .

388 *Microb Drug Resist* 2017; **23**: 966–972.

389	15	Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD. Multidrug
390		Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal
391		Resistance in Candida parapsilosis. Antimicrob Agents Chemother 2015; 59: 5942-
392		5950.
393	16	Ceballos-Garzon A, Wintaco-Martínez LM, Velez N et al. Persistence of clonal azole-
394		resistant isolates of Candida albicans from a patient with chronic mucocutaneous
395		candidiasis in Colombia. J Glob Infect Dis 2020; 12: 16-20.
396	17	Costa-De-Oliveira S, Rodrigues AG. Candida albicans Antifungal Resistance and
397		Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.
398		microorganisms 2020; <b>8</b> : 1–19.
399	18	Rojas AE, Pérez JE, Hernández JS et al. Análisis cuantitativo de la expresión de genes
400		de resistencia a fluconazol en cepas de Candida albicans aisladas al ingreso de adultos
401		mayores a una unidad de cuidados intensivos de Manizales, Colombia. Biomédica
402		2020; <b>40</b> : 153–165.
403	19	Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins
404		worldwide. Clin Microbiol Infect 2019; 25: 792–798.
405	20	Shapiro RS, Robbins N, Cowen LE. Regulatory Circuitry Governing Fungal
406		Development, Drug Resistance, and Disease. Microbiol Mol Biol Rev 2011; 75: 213-
407		267.
408	21	Costa-de-oliveira S, Rodrigues AG. Candida albicans antifungal resistance and
409		tolerance in bloodstream infections: The triad yeast-host-antifungal. Microorganisms.
410		2020; 8. doi:10.3390/microorganisms8020154.
411	22	Coste A, Turner V, Ischer F et al. A mutation in Tac1p, a transcription factor regulating

412		CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate
413		antifungal resistance in Candida albicans. Genetics 2006; 4: 2139–56.
414	23	Liu J-Y, Wei B, Wang Y et al. The H741D mutation in Tac1p contributes to the
415		upregulation of CDR1 and CDR2 expression in Candida albicans. Brazilian J
416		<i>Microbiol</i> 2020; <b>51</b> : 1553–1561.
417	24	Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of Antifungal
418		Drug Resistance. Cold Spring Harb Perspect Med 2014; 5: 019752.
419	25	Flowers SA, Colón B, Whaley SG, Schuler MA, David Rogers P. Contribution of
420		clinically derived mutations in ERG11 to azole resistance in Candida albicans.
421		Antimicrob Agents Chemother 2015; 59: 450–460.
422	26	Chow NA, Muñoz JF, Gade L et al. Tracing the evolutionary history and global
423		expansion of candida auris using population genomic analyses. MBio 2020; 11.
424		doi:10.1128/mBio.03364-19.
425	27	Ceballos-Garzon A, Amado D, Vélez N, Jiménez-A MJ, Rodríguez C, Parra-Giraldo
426		CM. Development and Validation of an in-House Library of Colombian Candida auris
427		Strains with MALDI-TOF MS to Improve Yeast Identification. J Fungi 2020; 6: 1–9.
428	28	CLSI. M27-A3 Reference Method for Broth Dilution Antifungal Susceptibility Testing
429		of Yeasts—Third Edition. Clin Lab Stand Inst 2008; 37: 1–2.
430	29	CLSI. M60ed1e: Performance Standards for Antifungal Susceptibility Testing of
431		Yeasts, 2nd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA. 2018.
432	30	CDC. Centers for Disease Control and Prevention. Antifungal Susceptibility Testing
433		and Interpretation to Laboratorians and Health Professionals. Access date: 07-07-21.
434		https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html.

- 435 2020.https://www.cdc.gov/fungal/candida-auris/ (accessed 10 Jul2021).
- 436 31 Tamura K, Stecher G, Kumar S. MEGA11: Molecular Evolutionary Genetics Analysis
  437 Version 11. *Mol Biol Evol* 2021; **38**: 3022–3027.
- 43832Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing
- 439 phylogenetic trees. *Mol Biol Evol* 1987; **4**: 406–425.
- 440 33 Gbelska Y, Toth Hervay N, Dzugasova V, Konecna A. Measurement of Energy-
- 441 dependent Rhodamine 6G Efflux in Yeast Species. *BIO-PROTOCOL* 2017; 7: 1–5.
- 442 34 Nucci M, Queiroz-Telles F, Alvarado-Matute T *et al.* Epidemiology of Candidemia in
- 443 Latin America: A Laboratory-Based Survey. *PLoS One* 2013; **8**: e59373.
- 444 35 Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the
- 445 SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-
- 446 2016. *Open Forum Infect Dis* 2019; **6**: \$79–\$94.
- 447 36 Cortés JA, Reyes P, Gómez C, Buitrago G, Leal AL. Fungal bloodstream infections in
  448 tertiary care hospitals in Colombia. *Rev Iberoam Micol* 2011; 28: 74–78.
- 449 37 Torres D NA, Álvarez M CA, Rondón S MA. Evaluación mediante tres técnicas de
- 450 susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con
- 451 infecciones invasoras: Bogotá Colombia. *Rev Chil infectología* 2009; **26**: 135–143.
- 452 38 Barahona-Correa J, Calvo-Valderrama M, Romero-Alvernia D *et al*. Epidemiology of
- 453 Candidemia at a University Hospital in Colombia. *Univ Medica* 2019; **60**: 1–9.
- 454 39 De bedout C, Ayabaca J, Vega R *et al.* Evaluation of Candida species' susceptibility to
  455 fluconazole with the disk diffusion method]. *Biomedica* 2003; 1: 31–37.
- 456 40 Sathi FA, Paul SK, Ahmed S et al. Prevalence and Antifungal Susceptibility of

457		Clinically Relevant Candida Species, Identification of Candida auris and Kodamaea
458		ohmeri in Bangladesh. Trop Med Infect Dis 2022; 7: 211.
459	41	Escribano P, Guinea J. Fluconazole-resistant Candida parapsilosis: A new emerging
460		threat in the fungi arena. Front Fungal Biol 2022; 0: 69.
461	42	Fekkar A, Blaize M, Bouglé A et al. Hospital outbreak of fluconazole-resistant candida
462		parapsilosis: Arguments for clonal transmission and long-term persistence. Antimicrob
463		Agents Chemother 2021; 65. doi:10.1128/AAC.02036-20/SUPPL_FILE/AAC.02036-
464		20-S000S1.PDF.
465	43	Mesini A, Mikulska M, Giacobbe DR et al. Changing epidemiology of candidaemia:
466		Increase in fluconazole-resistant Candida parapsilosis. <i>Mycoses</i> 2020; <b>63</b> : 361–368.
467	44	Corzo-Leon DE, Peacock M, Rodriguez-Zulueta P, Salazar-Tamayo GJ, MacCallum
468		DM. General hospital outbreak of invasive candidiasis due to azole-resistant Candida
469		parapsilosis associated with an Erg11 Y132F mutation. <i>Med Mycol</i> 2021; <b>59</b> : 664–671.
470	45	Thomaz DY, de Almeida JN, Sejas ONE et al. Environmental Clonal Spread of Azole-
471		Resistant Candida parapsilosis with Erg11-Y132F Mutation Causing a Large
472		Candidemia Outbreak in a Brazilian Cancer Referral Center. J Fungi 2021, Vol 7, Page
473		<i>259</i> 2021; <b>7</b> : 259.
474	46	Magobo RE, Lockhart SR, Govender NP. Fluconazole-resistant Candida parapsilosis
475		strains with a Y132F substitution in the ERG11 gene causing invasive infections in a
476		neonatal unit, South Africa. Mycoses 2020; 63: 471–477.
477	47	Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal
478		resistance in the opportunistic pathogenic fungus Candida albicans. J Antimicrob
479		<i>Chemother</i> 2020; <b>75</b> : 257–270.


480	48	Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal
481		therapy and its variable cost. J Antimicrob Chemother 2016; 71: 3599–3606.
482	49	Oliveira-Carvalho V, Del Negro GMB. Is the S405F mutation in Candida albicans
483		ERG11 gene sufficient to confer resistance to fluconazole? J Mycol Med 2014; 24:
484		241–242.
485	50	Debnath S, Addya S. Structural basis for heterogeneous phenotype of ERG11
486		dependent Azole resistance in C.albicans clinical isolates. Springerplus 2014; 3.
487		doi:10.1186/2193-1801-3-660.
488	51	Healey KR, Kordalewska M, Ortigosa CJ et al. Limited ERG11 mutations identified in
489		isolates of candida auris directly contribute to reduced azole susceptibility. Antimicrob
490		Agents Chemother 2018; 62. doi:10.1128/AAC.01427-18.
491	52	Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans
492		isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 27: 403-408.
493	53	Peron IH, Reichert-Lima F, Busso-Lopes AF et al. Resistance surveillance in Candida
494		albicans: A five-year antifungal susceptibility evaluation in a Brazilian University
495		Hospital. PLoS One 2016; 11. doi:10.1371/journal.pone.0158126.
496	54	Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid
497		substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-
498		resistant clinical isolates: new substitutions and a review of the literature. Diagn
499		Microbiol Infect Dis 2010; 66: 373–384.
500	55	Kumar A, Nair R, Kumar M et al. Assessment of antifungal resistance and associated
501		molecular mechanism in Candida albicans isolates from different cohorts of patients in
502		North Indian state of Haryana. Folia Microbiol 2020 654 2020; 65: 747–754.

- 503 56 Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of
- fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system.
- 505 Antimicrob Agents Chemother 2015; 59: 1030–7.
- 506 57 Choi YJ, Kim YJ, Yong D et al. Fluconazole-Resistant Candida parapsilosis
- 507 Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea. *Emerg*508 *Infect Dis* 2018; 24: 1768.
- 509 58 Thomaz DY, De Almeida JN, Lima GME *et al.* An azole-resistant candida parapsilosis
- 510 outbreak: Clonal persistence in the intensive care unit of a Brazilian teaching hospital.
- 511 *Front Microbiol* 2018; **9**: 2997.
- 512 59 Branco J, Silva AP, Silva RM et al. Fluconazole and voriconazole resistance in
- 513 Candida parapsilosis is conferred by gain-of-function mutations in MRR1 transcription
  514 factor gene. *Antimicrob Agents Chemother* 2015; **59**. doi:10.1128/AAC.00842-15.
- 515 60 World Health Organization (WHO). Fungal priority pathogens list to guide research,
- 516 development and public health action.
- 517 2022https://www.who.int/publications/i/item/9789240060241 (accessed 3 Nov2022).
- 518
- 519
- 520
- 521
- 522
- 523












533 Figure 1. Species distribution and overall fluconazole susceptibility results.


534 A) Distribution of the 123 species identified. B) Percentage of fluconazole resistance. The 535 number of isolates is indicated inside the bars. Susceptible (S) isolates are depicted in blue 536 and resistant (R) isolates in red.





541


Figure 2. Phylogenetic tree and amino acid substitutions found in fluconazole-resistant 542



- 544 amino acids. FLC: fluconazole; MIC: minimal inhibitory concentration. CA-S., Candida
- FLC-susceptible. Inside the colored squares, the number of substitutions found is indicated. 545

medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282939; this version posted December 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




547

548 Figure 3. Rhodamine 6G (R6G) efflux over time among fluconazole-resistant isolates.


549 Colored lines indicate the concentration of R6G released after the addition of 20 mM glucose

- (GLU). Data are means  $\pm$  SD from three experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.
- 551  $****p \le 0.0001$ . FLC: fluconazole; MIC: minimal inhibitory concentration.
- 552
- 553
- 554



557

- **Figure 4.** Schematic representation of the results obtained in this study for the 19 FLC-
- resistant isolates. In purple *C. albicans*, light blue *C. parapsilosis* and yellow *C. auris* isolates
- 560 with their respective MICs against FLC. In red font, the mutations found. The green stars
- indicate isolates with significant efflux pump activity. The size of the circle reflects the
- number of mutations, those not associated with FLC resistance (blue) and the new mutations(light green).



566 Figure 5. Countries reporting Erg11 substitutions in azole-resistant *C. parapsilosis*.

#### **Table 1**. Antifungal activity of fluconazole drug against *Candida* spp (n = 123) performed by CLSI.

## 

# 

#### MIC<sub>50</sub> and MIC<sub>90</sub> values (MICs at which $\geq$ 50% and $\geq$ 90% of the strains are inhibited, respectively) are depicted in bold and underlined,

Number (and cumulative percentage) of Candida spp strains with MIC μg/mL													Tatal										
Species	Drug	≤0.015	0.03	0.06	0.125	0.	.25	0.5	50	1	2	4		8	16	3	32	(	64	128	>128	- Total	Range
C. albicans	FLC	4 (9)	1 (11)		1 (13)	19	(54)	9 (	(74)	3 (80)	1 (83)	2 (87)								<u>4 (96)</u>	2 (100)	46	≤0.015 >128
C. auris	FLC										1 (10)		2	2 (30)				2	(50)		<u>5 (100)</u>	10	2->128
C. glabrata	FLC									1 (20)	1 (40)	2 (80)	<u>1</u>	(100)								5	1-8.
C. krusei	FLC												1	(33)	<u>2</u>	<u>(100)</u>						3	≤0.015
C. lusitaniae	FLC							-	_		<u>2 (100)</u>											2	2
C. parapsilosis	FLC	2 (8)			1 (13)			3 (	(25)	5 (46)	3 (58)	4 (75)			1 (79)	<u>3</u>	<u>(92)</u>	2	(100)			24	≤0.015-
C. tropicalis	FLC			4 (12)		6	(30)	10 (	(61)	3 (70)	<u>8 (94)</u>	2 (100	)									33	0.06-4
Overall																						123	